Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00069-1031-30 00069-1031 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 21, 2023 Dec 31, 2025 In Use
00054-0497-14 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 8, 2020 In Use
51991-0824-28 51991-0824 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct 1, 2021 In Use
50242-0210-86 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sep 15, 2020 Feb 11, 2022 In Use
59572-0983-01 59572-0983 Romidepsin Istodax Chemotherapy Enzyme Inhibitor HDAC Jan 4, 2010 In Use
46014-1195-03 46014-1195 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct 26, 2018 In Use
82950-0012-01 82950-0012 Tovorafenib OJEMDA 25.0 mg/ml Chemotherapy Enzyme Inhibitor BRAF, CRAF ORAL Apr 30, 2024 In Use
51991-0822-28 51991-0822 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Mar 5, 2021 In Use
50881-0020-60 50881-0020 Ruxolitinib Jakafi 20.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50242-0210-90 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Jul 1, 2021 In Use
50242-0210-12 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sep 28, 2022 In Use
00054-0481-14 00054-0481 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jun 8, 2020 In Use
71332-0006-12 71332-0006 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Jun 24, 2024 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 27, 2023 In Use
50242-0210-83 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Jul 1, 2021 In Use
50881-0010-60 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
72064-0210-90 72064-0210 pralsetinib GAVRETO 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sep 4, 2020 Apr 30, 2022 No Longer Used
00069-0296-30 00069-0296 talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct 26, 2018 Jan 31, 2027 In Use
00074-0576-30 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Jun 15, 2022 In Use
63850-0061-04 63850-0061 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 26, 2023 In Use
51991-0990-28 51991-0990 Everolimus Everolimus 2.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Jan 28, 2025 In Use
68152-0108-09 68152-0108 Belinostat Beleodaq 500.0 mg/10mL Chemotherapy Enzyme Inhibitor HDAC Intravenous Jul 21, 2014 Nov 30, 2022 In Use
73555-0501-00 73555-0501 Revumenib Revuforj 110.0 mg/1 Chemotherapy Enzyme Inhibitor KMT2A Oral Nov 15, 2024 In Use
71332-0005-01 71332-0005 Olutasidenib REZLIDHIA 150.0 mg/1 Chemotherapy Enzyme Inhibitor IDH1 Oral Dec 1, 2022 In Use
00310-0679-12 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug 17, 2017 In Use

Found 11564 results — Export these results